Excel Healthcare Group Identifies 2014 Healthcare Needs and Trends by Kristie Brown, Matthew Caravana, et al - HTML preview

PLEASE NOTE: This is an HTML preview only and some elements such as links or page numbers may be incorrect.
Download the book in PDF, ePub, Kindle for a complete version.


image005.gifClinical Quality Measures (CQM)

 

CMS (Centers for Medicare and Medicaid Services) has created clinical quality measures (or CQMs) that are used to measure and track the quality of healthcare services you receive as a patient. According to CMS.gov CQMs “measure many aspects of patient care including: health outcomes, clinical processes, patient safety, efficient use of healthcare resources, care coordination, patient engagements, population and public health, and clinical guidelines. Continuously measuring and reporting these CQMs helps to ensure that our health care system can deliver effective, safe, efficient, patient-centered, equitable, and timely care.”

These measures were created and became a requirement of Meaningful Use (MU) and for more information on the specifics of MU see the MU section of this book. With regards to ARRA (American Recovery and Reinvestment Act), everyone is required to report on core clinical quality measures and clinical quality measures selected from a list. If you don't collect the information on one or more of the core measures (or it reports zero), you replace them with other items from the list. These are not calculations but reports that are created from your EMR and the data reported as it appears on the report. There is not a minimum value to achieve - it just needs to be reported (for the requirements as of today).

Core Quality Measures required for MU:

NQF0013 Hypertension: Blood Pressure Measurement

NQF0028 Preventative Care and Screening Measurement Pair:

1)      Tobacco use assessment

2)      Tobacco Cessation Intervention

NQF0421/PQRI128 Adult Weight Screening and Follow-up

Additional List of Clinical Quality Measures:

1)      Diabetes: Hemoglobin A1c Poor Control

2)      Diabetes: Low Density Lipoprotein (LDL) Management and Control

3)      Diabetes: Blood Pressure Management

4)      Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

5)      Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD patients with prior Myocardial Infarction (MI)

6)      Pneumonia Vaccination status for older adults

7)      Breast cancer screening

8)      Colorectal cancer screening

9)      Coronary Artery Disease (CAD): Oral antiplatelet therapy prescribed for patients with CAD

10)   Heart Failure (HF): Beta-blocker therapy for Left Ventricular Systolic Dysfunction (LVSD)

11)   Anti-depressant medication management:

                a) Effective acute phase treatment

                b) Effective continuation phase treatment

12)   Primary Open Angle Glaucoma (POAG): Optic nerve evaluation

13)   Diabetic Retinopathy: Documentation of presence or absence of macular edema and level of security of retinopathy

14)   Diabetic Retinopathy: Communication with the physician managing ongoing diabetes care

15)   Asthma Pharmacologic Therapy

16)   Asthma Assessment

17)   Appropriate testing for children with pharyngitis

18)   Oncology Breast Cancer: Hormonal therapy for Stage IC-IIIC estrogen receptor/progesterone receptor (ER/PR) positive breast cancer

19)   Oncology Breast Cancer: Hormonal therapy for Stage III Colon cancer patients

20)   Prostate cancer: Avoidance of overuse of bone scan for staging low risk prostate cancer patients

21)   Smoking and Tobacco Use Cessation, Medical assistance:

                a) advising smoker and tobacco users to quit

                b) discussing smoking and tobacco use cessation medications

                c) discussing smoking and tobacco use cessation strategies

22)   Diabetes: Eye exam

23)   Diabetes: Urine screening

24)   Diabetes: Foot exam

25)   Coronary Artery Disease (CAD): Drug therapy for lowering LDL-Cholesterol

26)   Heart Failure (HF): Warfarin therapy patients with atrial fibrillation

27)   Ischemic Vascular Disease (IVD): Blood pressure management

28)   Ischemic Vascular Disease (IVD): Use of aspirin or another antithrombotic

29)   Initiation and engagement of alcohol and other drug dependence treatment

a)      initiation

b)      engagement

30)   Prenatal care: Screening for Human Immunodeficiency Virus (HIV)

31)   Prenatal Care: Anti-D Immune Globulin

32)   Controlling High Blood Pressure

33)   Cervical Cancer screening

34)   Chlamydia screening for women

35)   Use of appropriate medications for asthma

36)   Low back pain: Use of imaging studies

37)   Ischemic Vascular Disease (IVD): Complete lipid panel and LDL control

38)   Diabetes: Hemoglobin A1c Control (<8.0%)

 

These items may be modified in the future as each stage of Meaningful Use requires more of these CQM’s to be met in order to get ARRA funding. However, some of these measures could fail and not make it possible for providers to meet the qualifications. Some patients may have a contraindication to a treatment, and they do not account for those contraindications in these measures. Some patients may not react appropriately to certain treatment approaches and may need a different approach, but those are not accounted for in these measures either. We anticipate exclusions or exceptions for these measures. We expect some changes to the Clinical Quality Measures to come in the next few years as more clinical quality data is gathered and evaluated.

http://www.qualitymeasures.ahrq.gov is another good resource for more information on CQMs.